Labiotech.eu

apheabio microorganism biopesticides biostimulants

News and Trends 26 Jun 2017

New Belgian Biotech will use Microorganisms to Replace Pesticides and Fertilizers

Aphea.Bio has gathered a total of €9M in funding to start working on a new technology to produce biopesticides and biostimulants for European agriculture. Belgium has a new biotech that will be dedicated to developing sustainable, microorganism-based biopesticides and biostimulants. Aphea.Bio has raised €7.7M in a Series A round led by the Belgian life sciences investor V-Bio Ventures in addition to a €1.3M grant […]

June 26, 2017 - 1 minutemin - By Clara Rodríguez Fernández

Interview 26 Jun 2017

Meet the Gynecologist at the Helm of Geneva’s Star Biotech

Ernest Loumaye began as a doctor at a university hospital and is now CEO of ObsEva. We chatted about how biotech supports women’s health. ObsEva, one of the top biotechs in Geneva that made this year’s first IPO for a huge €90M, is not Ernest Loumaye’s first company. Though he began as the gynecologist in charge of the reproductive […]

June 26, 2017 - 5 minutesmins - By Evelyn Warner

type 1 diabetes insulin therapy uppsala university hospital

News and Trends 23 Jun 2017

Diabetic Patients that Still Produce Insulin might be the Key to a New Therapy

A study from Uppsala University has identified higher levels of interleukin-35 in type 1 diabetics that still produce insulin years after their diagnosis. Researchers at Uppsala University have published the first study in humans that shows the potential of interleukin-35 (IL-35) as a promising new target to treat type 1 diabetes. The results, published in […]

June 23, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

More News! 23 Jun 2017

French Biotech Raises Over €22M to Launch a Gene Therapy to Restore Sight

Gensight Biologics has announced a capital increase that totals €22.5M and will support the launch of its gene therapy for blindness in Europe and the US. Gensight has decided to give an additional financial push to its lead candidate, GS010, a gene therapy to restore sight in patients with the rare genetic disease Leber hereditary optic […]

June 23, 2017 - 1 minutemin - By Clara Rodríguez Fernández

Startup Scout 23 Jun 2017

This Newly Founded French Biotech is All About Vaccines

This week we visited the biotech hub Lyon, where one of our top biotechs Imaxio has recently founded Osivax to advance the development of its innovative vaccine candidates. Mission: Osivax was formed as a spin-off of Imaxio’s R&D department and develops a number of clinical and preclinical vaccine candidates based on its OligoDOM technology. This approach fuses specific immunogenic domains to […]

June 23, 2017 - 1 minutemin - By Melanie De Almeida

News and Trends 22 Jun 2017

French Nonprofit Partners with Big American Name to Advance a Gene Therapy for Muscular Dystrophy

Noble Généthon has teamed up with ignominious Sarepta to develop a gene therapy for the Duchenne variety of the muscle wasting disease. Dedicated to rare diseases since 1990 and more recently to gene therapy, Généthon is one of very few not-for-profit companies in European biotech. Though it has not yet brought a drug to market, it is […]

June 22, 2017 - 3 minutesmins - By Evelyn Warner

Interview 22 Jun 2017

Live Labiotech Hangout: Join our second webcast on synthetic biology, entrepreneurship and academia!

Join us for our second live Hangout with serial synbio entrepreneur but determined academic, Morten Sommer, which will be streaming live next week Thursday June 29th at 5:00pm CET! Click to Join the Hangout We can’t wait for an event to produce videos for our readers, and we realized we don’t have to! Next week is the second […]

June 22, 2017 - 1 minutemin - By Evelyn Warner

Novartis Cardiovascular Canakinumab Phase III

News and Trends 22 Jun 2017

Novartis Scores Major Phase III Win with New Cardiovascular Drug

Novartis just announced that its anti-inflammatory drug, canakinumab, was able to clear a 10,000-plus patient Phase III trial for cardiovascular disease. Novartis most recently boasted impressive Phase III results for its AMD drug, RTH258, that could yield the company a new blockbuster. Now, the Swiss drug maker announced that its cardiovascular drug, canakinumab, was able to meet its primary endpoint in […]

June 22, 2017 - 2 minutesmins - By Melanie De Almeida

Ose Immunotherapeutics bpifrance milestone bowel disease

News and Trends 22 Jun 2017

Immunotherapy for Bowel Disease Gets €2.6M Milestone Payment from Bpifrance

OSE Immunotherapeutics has successfully completed the necessary milestones to bring a treatment for autoimmune disease to the clinic, triggering a milestone payment from its partner Bpifrance. OSE Immunotherapeutics, based in Nantes, France, has received €2.6M from the French public investment agency Bpifrance after completing another milestone in the development of a therapy for inflammatory bowel disease. […]

June 22, 2017 - 1 minutemin - By Clara Rodríguez Fernández

cancer research uk grand challenge award

News and Trends 22 Jun 2017

What are the Biggest Cancer Challenges? The UK Offers £20M Prizes for Solutions!

Cancer Research UK is taking applications for £20M prizes from research groups worldwide that want to solve the biggest challenges in cancer research. Cancer Research UK is launching today its second round of the Grand Challenge to tear down some of the biggest barriers to the advancement of cancer therapy. The charity will shortlist the most promising […]

June 22, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 22 Jun 2017

LAB282 Awards Second Funding Round to 5 Academic Projects at Oxford

Evotec and the University of Oxford have announced the academic projects that will receive a financial award to push them towards launching spin-outs. LAB282 is a partnership between the German biotech Evotec, Oxford University Innovation and Oxford Sciences Innovation, the University’s venture fund manager. Set up with the aim to bridge academia and industry in life sciences, LAB282 […]

June 22, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

Interview 21 Jun 2017

Video: Can Synbio Cure Malaria? – Fireside Chat with Oxitec’s CEO Hadyn Parry

In our fireside chat with Hadyn Parry, Clara had the chance to hear all about Oxitec’s exciting technology that could save us from Dengue and Zika. Oxitec’s GM mosquitoes have the potential to halt epidemics of mosquito-borne diseases such as Zika or Dengue, which according to Hadyn are actually causing more problems every year. As Hadyn explained, “we’re […]

June 21, 2017 - 3 minutesmins - By Melanie De Almeida

Knowledge hub

Categories

Webinar: Organoids in cancer research - Paving the way for faster drug development across cancer indications

10 biotech companies leading the way in Denmark

Approaches

Therapeutic areas

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Webinar: Organoids in cancer research - Paving the way for faster drug development across cancer indications

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

New Belgian Biotech will use Microorganisms to Replace Pesticides and Fertilizers

Meet the Gynecologist at the Helm of Geneva’s Star Biotech

Diabetic Patients that Still Produce Insulin might be the Key to a New Therapy

French Biotech Raises Over €22M to Launch a Gene Therapy to Restore Sight

This Newly Founded French Biotech is All About Vaccines

French Nonprofit Partners with Big American Name to Advance a Gene Therapy for Muscular Dystrophy

Live Labiotech Hangout: Join our second webcast on synthetic biology, entrepreneurship and academia!

Novartis Scores Major Phase III Win with New Cardiovascular Drug

Immunotherapy for Bowel Disease Gets €2.6M Milestone Payment from Bpifrance

What are the Biggest Cancer Challenges? The UK Offers £20M Prizes for Solutions!

LAB282 Awards Second Funding Round to 5 Academic Projects at Oxford

Video: Can Synbio Cure Malaria? – Fireside Chat with Oxitec’s CEO Hadyn Parry

Subscribe to our newsletter to get the latest biotech news!

Webinar: Organoids in cancer research - Paving the way for faster drug development across cancer indications

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Webinar: Organoids in cancer research - Paving the way for faster drug development across cancer indications

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!